Abstract: The introduction of graphene as a carrier for enzymes and catalysts is disclosed.

Abstract: Provided is an adhesive sheet for affixation to the body which is excellent in enhancement and persistence of the blood circulation promoting action, has high affixability and conformability as a sheet, and is easily and widely applicable to the body in any use situation. That is, the present invention relates to an adhesive sheet for affixation to the body housed in a container, containing the following components (A) and (B): (A) bubbles containing carbon dioxide gas in a bubble fraction of 10% or more and 40% or less, and (B) water, wherein the total area occupied by bubbles having an imaginary diameter of 5 mm or more is 10% or less, in 100% of the surface area of the adhesive sheet for affixation to the body, a content of carbon dioxide gas in the total amount of the adhesive sheet for affixation to the body is from 100 to 20,000 ppm, and the adhesive sheet for affixation to the body is sealed in a low gas-permeable container.

Abstract: The present invention addresses the problem of providing phosphine for fumigation, by which clogging of a pipe of a fumigation gas feed device due to impurities is effectively suppressed and which has low spontaneous ignitability. The present invention also addresses the problem of providing a phosphine fumigation method in which clogging of a pipe of a fumigation gas feed device and a possibility of spontaneous ignition are reduced and which is safe. The phosphine for fumigation of the present invention has a P4 content of 10 mass ppm or less and a water content of 10 mass ppm or less. The fumigation method of the present invention includes fumigating a material to be fumigated, using phosphine having a P4 content of 10 mass ppm or less and having a water content of 10 mass ppm or less.

Abstract: The objective of the present invention is to provide a material to inhibit and/or remove a formation of a biofilm which material can be dispersed in water, of which effect can be sustained even in an environment such as water section, and which is highly safe and environmentally friendly. [Solution] The present invention relates to a fine particle comprising a complex consisting of a polycarboxylic acid derivative and a drug, wherein the fine particle is water-dispersible.

Abstract: A polymerizable compound is represented by the formula (I). Each R1 independently represents a monovalent group having from 3 to 12 carbon atoms that comprises at least one of an epoxy group, an acryl group, or a methacryl group. Each R2 independently represents H, F, Cl, Br, C1-C12 alkyl, C2-C3 carbonylalkyl, or C2-C5 carboalkoxy. Each R3 independently represents H, F, Cl, Br, C1-C12 alkyl, C2-C3 carbonylalkyl, or C2-C5 carboalkoxy. Each n is independently 0, 1, 2, 3, or 4. Curable compositions including the polymerizable compound are also disclosed.

Abstract: A method for preparing a dispersion of nanoparticles of a solid organic dye or pigment in a liquid carrier, and dispersions formed by such a method. The method includes continuously mixing: at least one solution or slurry containing a reactant precursor for the solid organic dye or pigment in an organic or other solvent with the liquid carrier in a counter current mixing reactor to obtain reaction of the reactant precursor and formation of the solid organic dye or pigment as a dispersion of nanoparticles in the liquid carrier and solvent mixture; optionally, removing unreacted reactant precursor and/or by-product from the dispersion when present; and optionally, concentrating the dispersion.

Abstract: An antibacterial air freshening product for an interior environment. The product includes a container containing 1 ml to 50 ml of a freshening composition in fluid communication with a membrane. The composition is substantially free of a surfactant and has from 0.5% to 20% of a volatile aldehyde mixture, by weight of the composition. The volatile aldehyde mixture includes a C5 to C8 unbranched unsubstituted linear alkenal and a C9 to C14 unbranched unsubstituted linear alkenal. A weight ratio of the C5 to C8 unbranched unsubstituted linear alkenal to the C9 to C14 unbranched unsubstituted linear alkenal is from 3:1 to 1:3.

Abstract: An oral care composition comprising high water oral care compositions comprising an orally acceptable carrier, zinc phosphate, a first stannous ion source (i.e., stannous fluoride), and a second stannous ion source (i.e., stannous chloride). Methods and uses for this composition are also described throughout.

Abstract: The present invention relates to an eco-friendly herbicide comprising 8 to 15% by weight of soft water, 1.5 to 5% by weight of canola oil, 0.2 to 1% by weight of potassium hydroxide, 78 to 88% by weight of pelargonic acid, 0.2 to 1% by weight of sodium alginate, 0.2 to 1% by weight of citric acid and 0.1 to 1% by weight of beet juice, and the herbicide provides the effects of being harmless to the human body and not causing soil contamination while exhibiting not only weed control but also bactericidal, insecticidal and harmful bird and animal repellent functions.

Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.

Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

Abstract: Lipid-based delivery vehicles are provided. Nanoparticulate compositions typically including a p21 activated kinase (PAK) inhibitor and a lipid-based delivery vehicle are also provided. In preferred embodiments, the lipid-based delivery vehicle is a liposome, most preferably a sterically-stabilized liposome. Typically the lipid-based delivery vehicle includes one or more phospholipids, and optionally a sterol. In some embodiments, at least one of the phospholipids is PEGylated. In particular embodiments, the lipid-based delivery vehicle includes DSPC, DSPE-PEG2000, and cholesterol. In specific embodiments, the ratio of DSPC, DSPE-PEG, and cholesterol is 9:1:5. The nanoparticulate composition typically includes a PAK inhibitor, preferably a PAK-1 inhibitor such as IPA-3 or a derivative, prodrug, or pharmaceutically acceptable salt thereof.

Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

Abstract: In some aspects, the techniques described herein relate to a topical dermatologic acne treatment method using a cream. The treatment method uses two steps, first providing a bactericidal component and second providing a skin revitalizing complex. The bactericidal component clears the acne causing bacteria. The subsequent skin revitalizing complex revitalizes and conditions the skin and aids in return of natural skin flora and microbiome to prevent subsequent outbreaks. The skin revitalizing complex can include a variety of components such as: niacinamide, retinol, bakuchiol, green coffee bean extract, green tea extract, epilobium fleischeri extract, citric acid, dimethicone, and pentaerythrityl tetracaprylate. The skin revitalizing complex restores natural elasticity and oil production of the skin, decrease sebum production, and provide necessary conditioning of the skin to provide for the natural skin flora and microbiome to repopulate and flourish on a surface of the skin.

Abstract: Polymeric transfection reagents for delivery of nucleic acids to cells, pharmaceutical compositions comprising same, and methods of preparing and using same are provided. A compound comprises polyethylenimine, a lipid selected from cholesterol, lauric acid, palmitic acid, or stearic acid, and optionally, a histidine. A nanoparticle comprises the compound complexed to a nucleic acid. A composition or pharmaceutical composition comprises the nanoparticle and a pharmaceutically acceptable carrier, anti-fouling agent, targeting ligand, or combinations thereof. A method of treating, preventing, or ameliorating a disease in a subject comprises administering to the subject an effective amount of the nanoparticle or the composition or pharmaceutical composition.

Abstract: A composition comprising: at least one compound of the chemical structure: [ H x ? O ( x - 1 ) 2 ] ? Z y wherein x is and odd integer ?3; y is an integer between 1 and 20; and Z is one of a monoatomic ion from Groups 14 through 17 having a charge value between ?1 and ?3 or a polyatomic ion having a charge between ?1 and ?3; or Z?—Hx?Ox?-y? wherein x? is and integer greater than 3 y? is an integer less than x?; and Z? is one of a monoatomic cation, a polyatomic ion or a cationic complex; and at least one of a humectant emollient or carrier.

Abstract: A composition comprising: at least one compound of the chemical structure: ? H x ? O ( x - 1 ) 2 ? ? Z y wherein x is an odd integer ?3; y is an integer between 1 and 20; and Z is one of a monoatomic ion from Groups 14 through 17 having a charge value between ?1 and ?3 or a polyatomic ion having a charge between ?1 and ?3; or Z?—Hx?Ox?-y? wherein x? is an integer greater than 3 y? is an integer less than x?; and Z? is one of a monoatomic cation, a polyatomic ion or a cationic complex; and at least one of a humectant emollient or carrier.

Abstract: The present disclosure discloses a method for inhibiting formation of a biofilm of bacteria. Specifically, the method may include treating the bacteria with an effective amount of a coumarin-chalcone compound. While inhibiting the formation of the biofilm of the bacteria, the effective amount of the coumarin-chalcone compound may reduce virulences of the bacteria and enhance a susceptibility of the bacteria to an antibiotic when applied in combination with the antibiotic. The present disclosure further discloses a composition including an effective amount of the coumarin-chalcone compound. The composition may be used to inhibit the formation of the biofilm of bacteria. The composition may also include an antibiotic, a minimal inhibitory concentration and a minimal biofilm eliminate concentration of which are reduced when the composition is used.

Abstract: ABSTRACT A cosmetic composition for skin containing a solvent A, a solvent B, and a polymer C, where a boiling point of the solvent A is lower than 99° C., and a distance Ra of the Hansen solubility parameter of the solvent A to water is 36 or less; a boiling point of the solvent B is 150° C. or higher, and a distance Ra of the Hansen solubility parameter of the solvent B to water is 40 or more; and the solvent B is compatible with the solvent A, and the polymer C is soluble in the solvent A but insoluble in the solvent B. A cosmetic coating film for skin includes the cosmetic composition.

Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).